Literature DB >> 24899991

Role of (18)F-FDG PET/CT, (123)I-MIBG SPECT, and CT in Restaging Patients Affected by Malignant Pheochromocytoma.

Antonio Cantalamessa1, Federico Caobelli2, Barbara Paghera3, Antonio Caobelli1, Francesca Vavassori1.   

Abstract

PURPOSE: Pheochromocytoma (PH) is a rare catecholamine-secreting tumor that arises from chromaffin tissue within the adrenal medulla and extra-adrenal sites; commonly it is sporadic, and malignant PH accounts for about 10% of all cases. Several imaging modalities have been used for the diagnosis and staging of this tumor: functional imaging using radio-labelled metaiodobenzylguanidine and, more recently, (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET/CT), which offers substantial sensitivity and specificity to correctly detect metastatic PH and helps to identify patients suitable for treatment with radiopharmaceuticals. The aim of our study was to compare CT, (18)F-FDG PET/CT, and (123)I-metaiodobenzylguanidine single photon emission tomography ((123)I-MIBG SPECT) as feasible methods to restage patients diagnosed histologically with PH.
METHODS: We retrospectively evaluated 38 patients (27 females and 11 males; mean age: 44 ± 15 years) with malignant PH documented histologically after surgical intervention. These patients underwent CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT.
RESULTS: (18)F-FDG PET/CT showed positive results for neoplastic tissue in 33/38 patients (86.8%) and negative in 5/38 (13.2%), in concordance with CT alone. (123)I-MIBG SPECT was positive in 30/38 patients (78,9%) and negative in 8/38 (21.1%). No differences in lesion numbers were found between (18)F-FDG PET/CT and CT, whereas a difference could be demonstrated between (18)F-FDG PET/CT and (123)I-MIBG SPECT.
CONCLUSION: (18)F-FDG PET/CT could more accurately restage patients with PH than CT and (123)I-MIBG SPECT, also in the absence of a staging study.

Entities:  

Keywords:  MIBG; PET; Paraganglioma; Pheochromocytoma; SPECT

Year:  2011        PMID: 24899991      PMCID: PMC4043021          DOI: 10.1007/s13139-011-0083-y

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  18 in total

1.  Multimodality imaging of malignant pheochromocytoma.

Authors:  Nazanene H Esfandiari; Barry L Shulkin; Chuong Bui; Craig A Jaffe
Journal:  Clin Nucl Med       Date:  2006-12       Impact factor: 7.794

2.  Superiority of F-18 FDG PET imaging for detection of a pheochromocytoma.

Authors:  Ravi Sood; Anna Story; Monica A Rossleigh; Walter Haindl; Jennifer Guille; Dilo Pillai
Journal:  Clin Nucl Med       Date:  2006-01       Impact factor: 7.794

3.  Brown adipose tissue demonstrating intense FDG uptake in a patient with mediastinal pheochromocytoma.

Authors:  Ichiei Kuji; Etsuko Imabayashi; Akinobu Minagawa; Hiroshi Matsuda; Tsutomu Miyauchi
Journal:  Ann Nucl Med       Date:  2008-05-23       Impact factor: 2.668

Review 4.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma.

Authors:  E L Bravo
Journal:  Endocr Rev       Date:  1994-06       Impact factor: 19.871

Review 5.  The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.

Authors:  K C Loh; P A Fitzgerald; K K Matthay; P P Yeo; D C Price
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

6.  Gene expression profiling of benign and malignant pheochromocytoma.

Authors:  Frederieke M Brouwers; Abdel G Elkahloun; Peter J Munson; Graeme Eisenhofer; Jennifer Barb; W Marston Linehan; Jacques W M Lenders; Ronald De Krijger; Massimo Mannelli; Robert Udelsman; Idris T Ocal; Barry L Shulkin; Stefan R Bornstein; Jan Breza; Lucia Ksinantova; Karel Pacak
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

7.  Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG.

Authors:  B L Shulkin; R A Koeppe; I R Francis; G M Deeb; R V Lloyd; N W Thompson
Journal:  Radiology       Date:  1993-03       Impact factor: 11.105

8.  Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy.

Authors:  Akie Takano; Noboru Oriuchi; Yoshito Tsushima; Ayako Taketomi-Takahashi; Takahito Nakajima; Yukiko Arisaka; Tetsuya Higuchi; Makoto Amanuma; Keigo Endo
Journal:  Ann Nucl Med       Date:  2008-07-04       Impact factor: 2.668

Review 9.  Can gallium-68 compounds partly replace (18)F-FDG in PET molecular imaging?

Authors:  Margarita Pagou; Imene Zerizer; Adil Al-Nahhas
Journal:  Hell J Nucl Med       Date:  2009 May-Aug       Impact factor: 1.102

10.  Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.

Authors:  Tomás Zelinka; Henri J L M Timmers; Anna Kozupa; Clara C Chen; Jorge A Carrasquillo; James C Reynolds; Alexander Ling; Graeme Eisenhofer; Ivica Lazúrová; Karen T Adams; Millie A Whatley; Jirí Widimsky; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2008-03       Impact factor: 5.678

View more
  6 in total

1.  Multifocal Head and Neck Paraganglioma Evaluated with Different PET Tracers: Comparison Between Fluorine-18-Fluorodeoxyglucose and Gallium-68-Somatostatin Receptor PET/CT.

Authors:  Paola Castaldi; Giorgio Treglia; Vittoria Rufini
Journal:  Nucl Med Mol Imaging       Date:  2013-05-07

2.  Diagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma.

Authors:  Teik Hin Tan; Zanariah Hussein; Fathinul Fikri Ahmad Saad; Ibrahim Lutfi Shuaib
Journal:  Nucl Med Mol Imaging       Date:  2015-04-08

3.  Marker-Negative Pheochromocytoma Associated with Inferior Vena Cava Thrombosis.

Authors:  S Poudyal; M Pradhan; S Chapagain; B R Luitel; P R Chalise; U K Sharma; P R Gyawali
Journal:  Case Rep Urol       Date:  2017-06-15

4.  Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience.

Authors:  Kranti Khadilkar; Vijaya Sarathi; Rajeev Kasaliwal; Reshma Pandit; Manjunath Goroshi; Gaurav Malhotra; Abhay Dalvi; Ganesh Bakshi; Anil Bhansali; Rajesh Rajput; Vyankatesh Shivane; Anurag Lila; Tushar Bandgar; Nalini S Shah
Journal:  Endocr Connect       Date:  2016-11-16       Impact factor: 3.335

5.  Imaging of Pheochromocytoma and Paraganglioma.

Authors:  Jorge A Carrasquillo; Clara C Chen; Abhishek Jha; Alexander Ling; Frank I Lin; Daniel A Pryma; Karel Pacak
Journal:  J Nucl Med       Date:  2021-08-01       Impact factor: 10.057

6.  68Ga-DOTATATE PET/CT Compared with 131I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors.

Authors:  Pezhman Shahrokhi; Alireza Emami-Ardekani; Sara Harsini; Mohammad Eftekhari; Armaghan Fard-Esfahani; Babak Fallahi; Najme Karamzade Ziarati; Mehdi Akhlaghi; Saeed Farzanefar; Amir Pejman Hashemi Taheri; Davood Beiki
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.